跳转至内容
Merck
CN
  • Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic Thrombocytopenia.

Insights Into Immunothrombotic Mechanisms in Acute Stroke due to Vaccine-Induced Immune Thrombotic Thrombocytopenia.

Frontiers in immunology (2022-05-28)
Nicole de Buhr, Tristan Baumann, Christopher Werlein, Leonie Fingerhut, Rabea Imker, Marita Meurer, Friedrich Götz, Paul Bronzlik, Mark P Kühnel, Danny D Jonigk, Johanna Ernst, Andrei Leotescu, Maria M Gabriel, Hans Worthmann, Ralf Lichtinghagen, Andreas Tiede, Maren von Köckritz-Blickwede, Christine S Falk, Karin Weissenborn, Ramona Schuppner, Gerrit M Grosse
摘要

During the COVID-19 pandemic, vaccination is the most important countermeasure. Pharmacovigilance concerns however emerged with very rare, but potentially disastrous thrombotic complications following vaccination with ChAdOx1. Platelet factor-4 antibody mediated vaccine-induced immune thrombotic thrombocytopenia (VITT) was described as an underlying mechanism of these thrombotic events. Recent work moreover suggests that mechanisms of immunothrombosis including neutrophil extracellular trap (NET) formation might be critical for thrombogenesis during VITT. In this study, we investigated blood and thrombus specimens of a female patient who suffered severe stroke due to VITT after vaccination with ChAdOx1 in comparison to 13 control stroke patients with similar clinical characteristics. We analyzed cerebral thrombi using histological examination, staining of complement factors, NET-markers, DNase and LL-37. In blood samples at the hyper-acute phase of stroke and 7 days later, we determined cell-free DNA, myeloperoxidase-histone complexes, DNase activity, myeloperoxidase activity, LL-37 and inflammatory cytokines. NET markers were identified in thrombi of all patients. Interestingly, the thrombus of the VITT-patient exclusively revealed complement factors and high amounts of DNase and LL-37. High DNase activity was also measured in blood, implying a disturbed NET-regulation. Furthermore, serum of the VITT-patient inhibited reactive oxygen species-dependent NET-release by phorbol-myristate-acetate to a lesser degree compared to controls, indicating either less efficient NET-inhibition or enhanced NET-induction in the blood of the VITT-patient. Additionally, the changes in specific cytokines over time were emphasized in the VITT-patient as well. In conclusion, insufficient resolution of NETs, e.g. by endogenous DNases or protection of NETs against degradation by embedded factors like the antimicrobial peptide LL-37 might thus be an important factor in the pathology of VITT besides increased NET-formation. On the basis of these findings, we discuss the potential implications of the mechanisms of disturbed NETs-degradation for diagnostic and therapeutic approaches in VITT-related thrombogenesis, other auto-immune disorders and beyond.

材料
货号
品牌
产品描述

Sigma-Aldrich
佛波醇12-十四酸酯13-乙酸酯, Phorbol-12-myristate-13-acetate, CAS 16561-29-8, is the most common phorbol ester. Activates PKC at nanomolar concentrations.
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 mg
预计发货时间 2025年4月27日
详情...
¥1,090.42
5 mg
预计发货时间 2025年4月27日
详情...
¥2,740.27
10 mg
预计发货时间 2025年5月13日
详情...
¥3,865.78
25 mg
预计发货时间 2025年5月13日
详情...
¥7,501.84
Sigma-Aldrich
IgG 来源于兔血清, reagent grade, ≥95% (SDS-PAGE), essentially salt-free, lyophilized powder
登录查看公司和协议定价
货号包装规格是否有货价格数量
10 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥1,164.89
50 mg
国内现货,预计发货时间 2025年4月21日
详情...
¥3,486.76
100 mg
预计发货时间 2025年4月24日
详情...
¥6,007.15
500 mg
预计发货时间 2025年6月23日
详情...
¥23,900.99
Millipore
MILLIPLEX®人细胞因子/趋化因子/生长因子组合A 38 Plex预混合磁珠试剂盒-免疫学多重分析
产品HCYTA-60K-PX38监管中,请联系销售询价或购买 联系客户支持
Sigma-Aldrich
山羊抗兔IgG抗体,HRP偶联物, 1 mg/mL, Upstate®
登录查看公司和协议定价
货号包装规格是否有货价格数量
500 μg
预计发货时间 2025年4月27日
详情...
¥3,422.53
Sigma-Aldrich
MPO活性检测试剂盒(比色法), sufficient for 100 colorimetric tests
登录查看公司和协议定价
货号包装规格是否有货价格数量
1 kit
请联系客服了解存货情况
¥7,900.80
Sigma-Aldrich
抗髓过氧化物酶抗体, from rabbit, purified by affinity chromatography
货号
包装规格
是否有货
价格
数量
Sigma-Aldrich
抗-DNA/组蛋白H1抗体, Chemicon®, from mouse
货号
包装规格
是否有货
价格
数量